Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Abstract Background To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (...

Full description

Bibliographic Details
Main Authors: Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Cholangiocarcinoma
Afatinib
BIBW 2992
Biomarkers
EGFR
panHER inhibition
Online Access:http://link.springer.com/article/10.1186/s12885-018-5223-7

Internet

http://link.springer.com/article/10.1186/s12885-018-5223-7

Similar Items